VEGFA and Hepatic fibrosis: Anti-angiogenic treatment with VEGF neutralising antibodies or the VEGF Receptor 2 inhibitor sorafenib can prevent fibrosis in BDL models of liver fibrosis (87, 88), although VEGF may also play a role in fibrosis resolution (88).